Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700697 | 0.90 | CA12 (0.43) | CA12CA1CA7CA14CA2 | |
| SCHEMBL21566414 | 0.87 | NR1D1 (0.33) | CA12CA1CA7CA14NR1D1 | |
| SCHEMBL26035581 | 0.85 | ALOX15 (0.33) | CA12CA1CA7CA14NR1D1 | |
| SCHEMBL16558068 | 0.84 | CA12 (0.39) | CA12CA1CA7CA14CA9 | |
| SCHEMBL16558064 | 0.81 | DNM1 (0.39) | CA12CA1CA7CA14 | |
| SCHEMBL16087987 | 0.81 | NR1D1 (0.32) | NR1D1NR1H3 | |
| SCHEMBL16558063 | 0.80 | CA12 (0.36) | CA12CA1CA7CA14CA2 | |
| SCHEMBL437106 | 0.80 | TDP1 (0.48) | CA1CA2NR1D1 | |
| SCHEMBL27420033 | 0.80 | NR1D1 (0.38) | CA12CA1CA7CA14CA2 | |
| SCHEMBL23711054 | 0.79 | CA12 (0.36) | CA12CA1CA7CA14NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731960-B2 | Biheterocyclic compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731960-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | CA12 3634/4885CA1 2806/4885CA7 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.